Download PDF
Thromb Haemost 2009; 102(02): 412-417
DOI: 10.1160/TH09-01-0032
New Technologies, Diagnostic Tools and Drugs
Schattauer GmbH

Novel evaluation method for densitometric curves of von Willebrand Factor multimers and a new parameter (MMW) to describe the degree of multimersation

Miklós L. Udvardy
1   Clinical Research Center, University of Debrecen, Debrecen, Hungary
2   Thrombosis, Haemostasis and Vascular Biology Research Group of the Hungarian Academy of Sciences, University of Debrecen, Debrecen, Hungary
,
Katalin Szekeres-Csiki
1   Clinical Research Center, University of Debrecen, Debrecen, Hungary
,
Jolán Hársfalvi
1   Clinical Research Center, University of Debrecen, Debrecen, Hungary
› Author AffiliationsFinancial support: This work was supported by Grants OTKA K62317, OTKA-NKTH NI 69238 (Hungarian Scientific Research Fund) and MTA 2006TKI227 (Hungarian Academy of Sciences).
Further Information

Publication History

Received: 14 January 2009

Accepted after major revision: 21 May 2009

Publication Date:
22 November 2017 (online)

    Permissions and Reprints

Summary

Von Willebrand factor (VWF) is built up from a varying number of subunits, of which the larger molecules have higher haemostatic activity. Von Willebrand disease (VWD) and thrombotic thrombocytopenic purpura are the best known disorders with pathognomonic changes of the highly multimerised VWF forms. There is an established method to calculate the relative amount of large oligomers. Our aim is to quantify the degree of VWF multimerisation as well, to complete the densitometric analysis of VWF electrophoresis. After optimisation, we have defined this new parameter (MMW) as the molecular weight corresponding to the lower boundary of the largest 25% of VWF protein. MMW was significantly different (p<.0001) in platelet lysate, normal samples and VWD type 2 samples (10.4, 6.3, 2.1, respectively). There was strong correlation between the MMW and the amount of large multimers in normal samples (r2=0.98) and in platelet lysate. However MMW was higher in latelet lysate, in which VWF is not cleaved by ADAMTS-13, than in healthy samples with the same amount of large multimers. Comparison of the new parameter and the collagen binding and ristocetin cofactor activity of VWF, showed that the functional tests are at least partially determined by the multimerisation; however, about 15% of VWD samples had normal activity to antigen ratios. The quantification of multimerisation aids the classification in these cases, especially at low antigen concentrations, and also might help in the detection of thrombotic conditions.

Keywords

VWF multimer analysis - von Willebrand disease

 

  • References

  • 1 Ruggeri ZM. Von Willebrand factor. Curr Opin Hematol 2003; 10: 142-149.
    CrossrefPubMedGoogle Scholar
  • 2 Marx I, Christophe OD, Lenting PJ. et al. Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa. Blood 2008; 112: 603-609.
    CrossrefPubMedGoogle Scholar
  • 3 Sadler JE. von Willebrand factor: two sides of a coin. J Thromb Haemost 2005; 03: 1702-1709.
    CrossrefPubMedGoogle Scholar
  • 4 Luken BM. Extracellular control of VWF multimer size and thiol-disulfide exchange. J Thromb Haemost 2008; 06: 1131-1134.
    CrossrefPubMedGoogle Scholar
  • 5 Tsai HM. Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency. Hematol Oncol Clin North Am 2007; 21: 609-632.
    CrossrefPubMedGoogle Scholar
  • 6 Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994; 71: 520-525.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Sadler JE, Budde U, Eikenboom JC. et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 04: 2103-2114.
    CrossrefPubMedGoogle Scholar
  • 8 Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 2008; 117: 1449-1459.
    CrossrefPubMedGoogle Scholar
  • 9 Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 2006; 95: 49-55.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Favaloro EJ, Thom J, Patterson D. et al. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: Differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?. Thromb Res 2009; 123: 862-868.
    CrossrefPubMedGoogle Scholar
  • 11 Raines G, Aumann H, Sykes S. et al. Multimeric analysis of von Willebrand factor by molecular sieving electrophoresis in sodium dodecyl sulphate agarose gel. Thromb Res 1990; 60: 201-212.
    CrossrefPubMedGoogle Scholar
  • 12 Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 1981; 57: 1140-1143.
    PubMedGoogle Scholar
  • 13 Smejkal GB, Shainoff JR, Kottke-Marchant KM. Rapid high-resolution electrophoresis of multimeric von Willebrand Factor using a thermopiloted gel apparatus. Electrophoresis 2003; 24: 582-587.
    CrossrefPubMedGoogle Scholar
  • 14 Studt JD, Budde U, Schneppenheim R. et al. Quantification and facilitated comparison of von Willebrand factor multimer patterns by densitometry. Am J Clin Pathol 2001; 116: 567-574.
    CrossrefPubMedGoogle Scholar
  • 15 Bowen JD, Bowley SJ. Improved visualisation of high-molecular-weight von Willebrand factor multimers. Thromb Haemost 2007; 97: 1051-1052.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Krizek DR, Rick ME. A rapid method to visualize von willebrand factor multimers by using agarose gel electrophoresis, immunolocalization and luminographic detection. Thromb Res 2000; 97: 457-462.
    CrossrefPubMedGoogle Scholar
  • 17 Weiss DR, Thiel C, Strasser EF. et al. An optimized electrophoresis method for high-resolution imaging of von-Willebrand multimers. Thromb Haemost 2008; 100: 949-951.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Budde U, Schneppenheim R, Eikenboom J. et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost 2008; 06: 762-771.
    CrossrefPubMedGoogle Scholar
  • 19 Gerritsen HE, Turecek PL, Schwarz HP. et al. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999; 82: 1386-1389.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Cejka J. Enzyme immunoassay for factor VIII-related antigen. Clin Chem 1982; 28: 1356-1358.
    PubMedGoogle Scholar
  • 21 Claus RA, Bockmeyer CL, Budde U. et al. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost 2009; 101: 239-247.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Lopes AA, Soares RP, Maeda NY. A mathematical framework for group analysis of von Willebrand factor multimeric composition following luminography. Braz J. Med Biol Res 2002; 35: 1259-1263.
    CrossrefPubMedGoogle Scholar
  • 23 Mazurier C, Dieval J, Jorieux S. et al. A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction. Blood 1990; 75: 20-26.
    PubMedGoogle Scholar